Every woman who lives past midlife will experience menopause, which, by definition, is
complete cessation of ovarian function. This process might occur spontaneously (natural …

Importance Menopause, due to loss of ovarian follicular activity without another pathological
or physiological cause, typically occurs between the ages of 45 years and 56 years. During …

Abstract The International Menopause Society (IMS) has produced these new 2016
recommendations on women's midlife health and menopause hormone therapy (MHT) to …

Objective This pilot study aimed to assess the efficacy and feasibility of fractional CO2 laser
in the treatment of vulvovaginal atrophy (VVA) in postmenopausal women. Methods VVA …

Abstract Introduction Hypoactive Sexual Desire Disorder (HSDD) is defined in the
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV-TR) …

Sexual dysfunction in women is a common and often distressing problem that has a
negative impact on quality of life and medication compliance. The problem is often …

The term genitourinary syndrome of menopause (GSM) emerged following a consensus
conference held in May 2013. GSM is a more descriptive term than vulvovaginal atrophy …

The aim of this review is to provide an overview of genitourinary health in peri-and
postmenopause, particularly of vulvovaginal atrophy (VVA), which is part of genitourinary …

Background Ospemifene is a non-estrogen, tissue selective estrogen receptor
agonist/antagonist, or selective estrogen receptor modulator, recently approved for the …

Low or absent sexual desire is the most common sexual dysfunction in women, and its
prevalence peaks during midlife. Its etiology is complex and may include biologic …